Saturday, March 2, 2024

CATEGORY

Amgen

Competition Heats Up for First-Line KRAS Inhibitor in Lung Cancer Treatment

In the relentless quest to combat KRAS-mutated non-small cell lung cancer (NSCLC), Amgen's Lumakras and Mirati's Krazati have secured approval for second-line treatment. However,...

Latest news

Sticky Image